Skip to main content
Download PDF

Erratum to: ‘Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial

Trials volume 17, Article number: 63 (2016) Cite this article

The Original Article was published on 16 December 2015

Unfortunately, the original version of this article [1] contained a few formatting errors which have been corrected via an update. In the eighth paragraph of the background there was an error. The original read as, “A phase II study evaluating the combination of nab-paclitaxel plus carboplatin as 199 first-line treatment for mTNBC is currently under way [31].” But should have read as “A phase II study evaluated the combination of nab-paclitaxel plus carboplatin a first-line treatment for mTNBC [31].”

Reference

  1. Yardley DA, Brufsky A, Coleman RE, Conte PF, Cortes J, Glück S, et al. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial. Trials. 2015;16:575.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sarah Cannon Research Institute and the Tennessee Oncology, PLLC, 250 25th Avenue North, Suite 100, Nashville, TN, 37203, USA

    Denise A. Yardley

  2. University of Pittsburgh Medical Center, Pittsburgh, PA, USA

    Adam Brufsky

  3. Weston Park Hospital, Sheffield Cancer Research Center, Sheffield, England

    Robert E. Coleman

  4. Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, and Istituto Oncologico Veneto IRCCS, Padova, Italy

    Pierfranco F. Conte

  5. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain

    Javier Cortes

  6. Celgene Corporation, Summit, NJ, USA

    Stefan Glück, Robert M. Beck, Amy Ko, Markus F. Renschler & Debora Barton

  7. Centre de Lutte Contre le Cancer d’Auvergne, Clermont Ferrand, France

    Jean-Mark A. Nabholtz

  8. Texas Oncology-Baylor Charles A. Sammons Center; US Oncology, Dallas, TX, USA

    Joyce O’Shaughnessy

  9. Breast Center, University of Munich, Munich, Germany

    Nadia Harbeck

Authors
  1. Denise A. Yardley
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Adam Brufsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert E. Coleman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pierfranco F. Conte
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Javier Cortes
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Stefan Glück
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jean-Mark A. Nabholtz
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Joyce O’Shaughnessy
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Robert M. Beck
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Amy Ko
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Markus F. Renschler
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Debora Barton
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Nadia Harbeck
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Denise A. Yardley.

Additional information

The online version of the original article can be found under doi:10.1186/s13063-015-1101-7.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yardley, D.A., Brufsky, A., Coleman, R.E. et al. Erratum to: ‘Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial. Trials 17, 63 (2016). https://doi.org/10.1186/s13063-016-1195-6

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s13063-016-1195-6

Trials

ISSN: 1745-6215